May 19, 2016
November 2014, Part 4
Immunotherapy: Early Success in Melanoma Provides Hope for Success in Other Cancers
Dear Colleague, Immunotherapy is a term we have heard for years, if not decades, but the fruits of researchers’ labor have just recently begun to be realized, most notably in the field of melanoma. As a result, so many of us associate immunotherapy with melanoma. True, we have seen great [ Read More ]
Letter to Our ReadersImmunotherapy and the Moon Shots Program:
An Interview with Dr James Allison of MD Anderson Cancer Center
Harnessing the power of the immune system to combat cancer is not a new idea; however, the new generation of immunotherapeutic agents have captured the imagination of those in the oncology community and sparked a renewed interest in the potential capabilities of an empowered immune system. As a result, immunotherapy [ Read More ]
Interview with the InnovatorsTargeted Agents, Immunotherapy, and Other Treatments Are Emerging for Cutaneous Malignancies
Malignant Melanoma Interferon remains the adjuvant therapy of choice in patients at high risk for recurrence of malignant melanoma, said Reinhard Dummer, MD. A systematic review favored high-dose interferon versus observation on relapse-free survival but not overall survival (OS) in patients with high-risk resected primary melanoma. Recently, however, relapse-free survival [ Read More ]
New Drugs and Clinical Trial Data: Updates in Cutaneous Malignancies
Immune-targeted therapies and inhibitors of Hedgehog pathway signaling dot the landscape in recent investigations in the treatment of melanoma, BCC, and MCC. A rundown of findings with newly approved therapies and investigational therapies was presented at the Third Annual World Cutaneous Malignancies Congress. Immune Therapies in Melanoma In the treatment [ Read More ]
Immunotherapeutic Strategies for Improving Patient Outcomes: Presentations From the European Society for Medical Oncology
Immunotherapy is the hot topic on everyone’s mind in the oncology community, and there are numerous research studies focusing on how to optimally provide immunotherapeutic strategies to ultimately improve patient outcomes. At the European Society for Medical Oncology (ESMO) 2014 Congress, many exciting presentations outlined the work being done to [ Read More ]